Nasdaq · Biotech stocks database
ICLR — ICON plc
ICLR (ICON plc) stock: $168.45, $12.90B market cap, $647.3M cash, $16.06B EV, $12.90B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Assets
Pipeline
Trials
Holders
Enterprise value
$16,056.7M
Balance sheet
Cash $647.3M Debt $3,806.2M Net cash -$3,158.9M Enterprise value $16,056.7M Basic shares 76.6M shares Fully diluted shares 76.6M shares Fully diluted market cap $12,897.8M Cash per share $8.45
Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history Loading ICLR daily closes…
Loading price history…
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Jan 11 - Feb 22 Jynneos Phase 2 Monkeypox (Mpox) — Nov 12 - Dec 24 SP-420 Phase 2 Beta Thalassemia Major Anemia; Myelodysplastic Syndrome — Mar 9 - Apr 20 Anifrolumab Phase 3 Systemic Lupus Erythematosus — Apr 11 - May 23 Camizestrant Phase 3 ER-Positive HER2-Negative Breast Cancer — Nov 8 - Dec 20 Belimumab Phase 3 Connective Tissue Diseases —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT05710692 Phase 3 Recruiting Collaborator Chiesi Farmaceutici S.p.A. — Fabry Disease — NCT06328608 Phase 3 Recruiting Collaborator Chiesi Farmaceutici S.p.A. — Fabry Disease — NCT07430306 Phase 3 Recruiting Collaborator AZN AZN Systemic Lupus Erythematosus — NCT07647328 Phase 3 Recruiting Collaborator AZN AZN ER-Positive HER2-Negative Breast Cancer — NCT06716606 Phase 3 Recruiting Collaborator GSK GSK Connective Tissue Diseases — NCT04620239 Phase 3 Active, not recruiting Collaborator Steba Biotech S.A. — Transitional Cell Cancer of Renal Pelvis and Ureter — NCT03513939 Phase 2 Active, not recruiting Collaborator Sernova Biotherapeutics Inc. — Type 1 Diabetes Mellitus — NCT07199569 Phase 2 Active, not recruiting Collaborator Bavarian Nordic — Monkeypox (Mpox) — NCT05693909 Phase 2 Recruiting Collaborator Pharmacosmos A/S — Beta Thalassemia Major Anemia; Myelodysplastic Syndrome — NCT07514338 Phase 2 Not yet recruiting Collaborator Pharming Technologies B.V. — Mitochondrial Diseases — NCT04844866 Phase 2 Recruiting Collaborator Miltenyi Biomedicine GmbH — Diffuse Large B-cell Lymphoma — NCT05997264 Phase 2 Active, not recruiting Collaborator Biomedical Advanced Research and Development Authority — Anthrax —
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 23 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 23 active trials for Chiesi Farmaceutici S.p.A. on ClinicalTrials.gov
No specialist-fund holders in 13F data for this company.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.